Tech Times on MSN
Oral drug MB-388 enters human testing, targeting cancer's immune silencing that defeats checkpoint therapy
Mondego Bio doses first humans with oral MB-388, an immunotherapy-resistance drug targeting the PTPN2/PTPN1 pathway. Phase 1a data expected December 2026.
Researchers developed the first TNKS2-selective inhibitor, TDI-012804, which suppresses WNT signaling in cancer cells lacking ...
A narrative review links an imbalance between kynurenic acid and quinolinic acid in the kynurenine pathway to seizures, drug ...
A new study led by King's College London has found that chemotherapy helps attract a specific population of immune cells ...
Unsweetened black and green tea modestly lowered blood sugar in studies, but adding sugar erased the benefit, researchers ...
Paradigm-shifting phase 3 trial data show that B-cell modulating therapies are having remarkable effects in IgA nephropathy.
A small subset of vulnerable DNA sites can make cancer cells highly sensitive to targeted drugs called PARP inhibitors, a new ...
New INTEGUMENT-3 study to evaluate efficacy, safety, and tolerability of investigational ZORYVE® cream 0.3% in individuals with moderate to ...
CEO Frank Gleeson and Chief Medical Officer Wildon Farwell will speak at 8 a.m. ET Nov. 6; slides are available with the ...
In a laboratory south of San Francisco, scientists will soon be hard at work training their replacements. Technicians wearing ...
Could a new drug-development strategy help protect brain cells from damage caused by neurodegenerative diseases? Researchers ...
A small subset of vulnerable DNA sites can make cancer cells highly sensitive to targeted drugs called PARP inhibitors, a new study shows.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results